IRWD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ironwood Pharmaceuticals Inc (IRWD) is not a strong buy at this moment for a beginner investor with a long-term horizon. The technical indicators show a bullish trend, but the overbought RSI and weak financial performance raise concerns. Additionally, insider selling and lack of significant positive catalysts suggest caution. Holding the stock or waiting for a better entry point is recommended.
The MACD is positive and expanding (0.13), indicating bullish momentum. The RSI is at 81.366, signaling overbought conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 4.294 and 4.562, with support at 3.86 and 3.427.
Bullish technical indicators, including MACD and moving averages. Analyst Jason Butler raised the price target to $10 and reiterated confidence in the company's 2026 guidance.
Insiders are selling significantly (22659.51% increase in the last month). Financial performance in Q4 2025 was weak, with revenue down 47.31% YoY, net income down 200.89% YoY, and EPS down 300%. No significant news or recent congress trading data.
In Q4 2025, revenue dropped to $47.71M (-47.31% YoY), net income fell to -$2.28M (-200.89% YoY), and EPS declined to -0.02 (-300% YoY). Gross margin remained at 100%.
Citizens analyst Jason Butler raised the price target to $10 from $8 and maintained an Outperform rating, citing confidence in 2026 guidance and cash flow potential.
